Primary Immunodeficiency (PID)
Conditions
Keywords
PID, SCIG, Ig, Quality of Life, Serious Bacterial Infections
Brief summary
This study aims to assess the safety, tolerability, efficacy and pharmacokinetics of Ig NextGen 16% in people with antibody deficiency currently being treated with IntragamP. Ig NextGen 16% is a liquid immunoglobulin (antibody) preparation manufactured using predominately chromatographic techniques. Eligible patients will switch from monthly intravenous IntragamP therapy to weekly subcutaneous Ig NextGen 16% treatment. Initial hospital training will be required for subcutaneous administration and then the patient will perform the infusion in their own home, returning once a month for a supervised infusion. Patients will be monitored on the study for up to 10 months to assess blood IgG levels and rate of serious bacterial infections.
Interventions
DRUGIgNextGen 16%
IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
Sponsors
CSL Limited
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Inclusion Criteria: * Males or females 3 years of age or greater and at least 13 kg at enrolment. * PID patients receiving Ig replacement therapy, with a diagnosis of X-linked agammaglobulinemia (XLA) or Common Variable immunodeficiency (CVID) with severe hypogammaglobulinemia. * Patients who have received a consistent dose of Intragam®P at 3-, 4-, 5- or 6-weekly intervals, within the range of 0.2 - 0.6 g/kg body weight, for at least six months prior to the Screening visit. * Patients must have maintained IgG trough serum level of ≥ 5 g/L during the six months prior to Visit 0, with at least two trough levels to have been documented during this period. * Patients and/or their legally acceptable representative/guardian must give written informed consent to participate in the study and must understand the nature of the study and must be willing to comply with all protocol requirements
Exclusion criteria
* • Patients newly diagnosed with PID within six months of the Screening visit. * Patients with known or suspected severe hypersensitivity or previous evidence of severe side effects to immunoglobulin therapy or other blood products * Patients with known selective IgA deficiency or antibodies to IgA * Patients receiving immunosuppressive treatment other than topical and/or inhaled steroids and low dose oral steroids. * Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Females who are of child bearing potential must have a negative pregnancy test at screening. * Patients with protein-losing enteropathies, and kidney diseases with substantial proteinuria * Patients with malignancies of lymphoid cells such as chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma and immunodeficiency with thymoma. * Patients who have within 30 days priors to the study screening visit, participated in a clinical study or used an investigational compound (eg: a new chemical entity not registered for clinical use). * Patients with any of the following abnormal lab results: * Serum creatinine \>1.5 x Upper limit of Normal (ULN). * Serum ALT & AST \> 2.5 x ULN. * Albumin \< 25 g/L * Patients who are suffering from an acute or chronic medical condition, other than PID, which may, in the opinion of the Investigator, affect the conduct of the trial. * Patients who are not willing or are unable to comply with protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy | Continually from Visits 7 to 12 & monthly IgG troughs |
Secondary
| Measure | Time frame |
|---|---|
| Safety, Tolerability, Quality of Life, Pharmacokinetics | Visits 0, 6, 9, and12 |
Countries
Australia, New Zealand
Outcome results
None listed